Predictive Genetic Tests and Health Care Costs: A Policy Framework and Illustrative Estimates

Fiona Miller (), Jeremiah Hurley, Steve Morgan, Fiona Miller (), Patricia Collins, Gordon Blackhouse, Mita Giacomini () and Bernie O'Brien
Additional contact information
Fiona Miller: Centre for Health Economics and Policy Analysis, Department of Clinical Epidemiology and Biostatistics, McMaster University
Steve Morgan: Centre for Health Services and Policy Research, University of British Columbia
Fiona Miller: Department of Clinical Epidemiology and Biostatistics, McMaster University, Centre for the Evaluation of Medicines, St. Josesph's Hospital
Patricia Collins: Centre for Health Economics and Policy Analysis, McMaster University
Gordon Blackhouse: Department of Clinical Epidemiology and Biostatistics, McMaster University, Centre for the Evaluation of Medicines, St. Joseph's Hospital
Mita Giacomini: Centre for Health Economics and Policy Analysis, Department of Clinical Epidemiology and Biostatistics, McMaster University
Bernie O'Brien: Centre for Health Economics and Policy Analysis, Department of Clinical Epidemiology and Biostatistics, McMaster University

No 2002-03, Centre for Health Economics and Policy Analysis Working Paper Series from Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada

Abstract: Genetic testing has long been part of Canada’s health system, but the scope of genetic testing is growing into new areas. Whereas traditional tests predominantly foretell the health of future generations, new tests increasingly tell individuals about their own health and risks. And whereas traditional tests have focused on rare, single-gene, genetically determined disorders, new tests target common, complex, and multifactorial diseases in which genetics plays only a part. These trends lead to unprecedented clinical and popular interest in genetic tests, and the expanded use of testing will affect both population health and health care costs. Whether the net effects will be positive or negative is a matter of heated debate. Early policy decisions about how tests will be disseminated, provided, and funded will greatly influence the cost and other impacts of new predictive genetic tests. This report examines the potential effect of new predictive genetic test services on health care costs. We offer a general framework that identifies key factors determining the cost impact of a predictive genetic test service and suggests how the choices of health system decision makers influence costs. We also present cost analyses of four specific predictive genetic tests. The report focuses solely on financial cost implications from the formal health care system’s point of view, and does not address the very important questions of impacts on health, wellbeing, productivity, societal costs, or informal care giving. The cost impact of a predictive genetic test depends on, among other things, characteristics of the test, the scope of its application, and the changes in health care utilization (disease surveillance, prevention, and treatment) induced by the test result. For many tests, the cost of performing the test itself makes up only a small proportion of the total health care costs that follow from its use.

Pages: 93 pages
Date: 2002
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.chepa.org/Files/Working%20Papers/02-03.pdf First version, 2002 (application/pdf)
Our link check indicates that this URL is bad, the error code is: 404 Not Found

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hpa:wpaper:200203

Access Statistics for this paper

More papers in Centre for Health Economics and Policy Analysis Working Paper Series from Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada Contact information at EDIRC.
Bibliographic data for series maintained by Lyn Sauberli ( this e-mail address is bad, please contact ).